Key points from article :
SENISCA, a biotech company focusing on RNA-based treatments for age-related diseases, secured £3.7 million in funding.
A total funding of £7.1 million and an additional £1.1 million from grants and commercial revenue.
Funds to further develop SENISCA's senotherapeutic programs that target RNA splicing dysregulation to address cellular senescence.
This approach can be specifically targeted in the context of multiple pharmacological and skin health indications.
Sarah Cole, CEO of SENISCA, said: “We look forward to rapidly advancing towards becoming a world-leader in the development and use of senotherapeutics to treat complex disease.”
Richard Haycock, CEO of QantX, said: “..looking forward to working with the Company’s disruptive senotherapeutic technology.”
